Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi Sells 1,404 Shares of Stock

Aura Biosciences, Inc. (NASDAQ:AURA) SVP Amy Elazzouzi sold 1,404 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total value of $10,881.00. Following the transaction, the senior vice president now directly owns 82,278 shares in the company, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Amy Elazzouzi also recently made the following trade(s):

• On Tuesday, January 21st, Amy Elazzouzi sold 1,001 shares of Aura Biosciences stock. The stock was sold at an average price of $7.67, for a total value of $7,677.67.

Aura Biosciences Stock Down 3.8 %

AURA stock opened at $7.65 on Wednesday. The company’s 50-day simple moving average is $8.07 and its 200-day simple moving average is $8.76. Aura Biosciences, Inc. has a 52-week low of $6.63 and a 52-week high of $12.38. The firm has a market cap of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29.

Analyst Ratings Changes

AURA has been the topic of several research reports. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AURA. Long Focus Capital Management LLC lifted its stake in Aura Biosciences by 123.9% in the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company’s stock valued at $20,861,000 after buying an additional 1,404,228 shares in the last quarter. Levin Capital Strategies L.P. lifted its stake in Aura Biosciences by 169.1% in the 4th quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company’s stock valued at $10,255,000 after buying an additional 783,984 shares in the last quarter. B Group Inc. purchased a new position in Aura Biosciences in the 4th quarter valued at about $3,885,000. Franklin Resources Inc. lifted its stake in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after buying an additional 215,597 shares in the last quarter. Finally, Ensign Peak Advisors Inc lifted its stake in Aura Biosciences by 43.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 390,695 shares of the company’s stock valued at $3,212,000 after buying an additional 118,000 shares in the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.